| 📌 The essentials On April 2, 2026, the FDA accepted for review the resubmitted Biologics License Application (BLA) for UX111 (rebisufligene etisparvovec), an AAV9 gene therapy developed by Ultragenyx Pharmaceutical for Sanfilippo syndrome Type A (MPS IIIA). PDUFA date: September 19, 2026. Regulatory history: the FDA previously granted UX111 Priority Review in February 2025. The BLA was originally submitted, received a Complete Response Letter, and was resubmitted in January 2026 with additional long-term clinical data agreed upon with the FDA. The clinical basis: up to 8 years of follow-up showing sustained, significant reductions in CSF heparan sulfate and continued functional improvements compared with natural history, including a 23.2-point Bayley-III cognitive gain (p less than 0.0001) in early-stage patients and median 63.98% CSF heparan sulfate reduction (p less than 0.001). If approved: UX111 would be the first approved therapy for MPS IIIA. There are currently no disease-modifying treatments for this condition. The disease: Sanfilippo syndrome Type A is a rare, fatal lysosomal storage disorder causing progressive neurodegeneration in young children, with a median life expectancy of approximately 15 years. |
|---|
Some diseases are called rare because they affect a small number of people. Sanfilippo syndrome is rare in a different sense. It is rare in the way that makes people who learn about it stop mid-sentence. It is a genetic disease that affects young children, causes their nervous systems to progressively deteriorate, and kills most of them in their teenage years. It has no approved treatment.
Children with Sanfilippo syndrome often appear developmentally normal in early infancy. The first signs, typically behavioral changes and developmental regression, usually emerge between ages 2 and 6, after parents have already formed complete pictures of who their child is. Then the regression accelerates. Language disappears. Motor skills deteriorate. Most children lose the ability to walk, eat independently, and communicate. Median life expectancy is approximately 15 years.
On April 2, 2026, Ultragenyx Pharmaceutical announced that the FDA has accepted for review its resubmitted Biologics License Application for UX111 (rebisufligene etisparvovec), a one-time intravenous gene therapy for Sanfilippo syndrome Type A. The FDA set a PDUFA action date of September 19, 2026. The clinical data behind this application includes up to eight years of follow-up in treated patients, and the results represent the most robust evidence ever generated for a potential treatment of this disease.
This post covers what Sanfilippo syndrome Type A is and what it does to the children who have it, how UX111 works, what the clinical trial data actually shows, the regulatory history that preceded this acceptance, and what families and clinicians need to understand about where the program stands.
What Sanfilippo Syndrome Type A Is
Mucopolysaccharidosis type III (MPS III), also known as Sanfilippo syndrome, is a group of four subtypes (A, B, C, and D) caused by different enzyme deficiencies, all of which result in the accumulation of heparan sulfate, a long-chain sugar molecule, within cells throughout the body. The brain is particularly affected because neurons are especially sensitive to this toxic accumulation.
Sanfilippo syndrome Type A (MPS IIIA) is the most common and most severe subtype. It is caused by mutations in the SGSH gene, which encodes the enzyme sulfamidase (also called heparan-N-sulfatase). Without functional sulfamidase, heparan sulfate cannot be broken down and accumulates progressively in lysosomes throughout neural and other tissues.
The disease follows a characteristic three-phase progression:
Phase 1: Developmental delay or regression, typically appearing between ages 2 and 6. Behavioral symptoms are often prominent, including hyperactivity, aggression, and sleep disturbance. This phase can last several years.
Phase 2: Severe neurological decline. Language is lost, motor skills deteriorate, and seizures become common. Behavioral symptoms often intensify before this phase.
Phase 3: Final stage, characterized by profound neurological impairment, loss of ambulation, and complete dependence for all care. Death typically occurs between ages 10 and 20 in most patients, though some survive longer.
An estimated 3,000 to 5,000 children worldwide have MPS IIIA. In the United States, approximately 1 in 100,000 live births is affected. There are currently no approved disease-modifying treatments in any country.
| The heparan sulfate accumulation problem: why it is so damaging and so hard to treat Heparan sulfate (HS) is a normal component of the extracellular matrix and cell surface in virtually all tissues. The breakdown of heparan sulfate requires a sequential series of enzymes; if any one of them is deficient, partially broken-down HS fragments accumulate in lysosomes. The accumulation is not static: it worsens progressively with age as the substrate burden grows. In the brain, heparan sulfate accumulation triggers inflammatory pathways, impairs autophagy (the cellular waste-disposal process), and causes progressive neuronal death. Because the blood-brain barrier prevents large proteins like enzyme replacements from reaching the central nervous system in therapeutic concentrations, the standard treatment approach for many lysosomal storage disorders, enzyme replacement therapy (ERT), has not been effective for MPS IIIA. ERT can address peripheral manifestations but cannot adequately cross the blood-brain barrier to address the primary site of pathology. This is why gene therapy, which can deliver a functional gene directly into cells that will express the enzyme continuously, is being pursued as the mechanism most likely to address the neurological aspects of the disease. |
|---|
How UX111 Works
UX111 (rebisufligene etisparvovec) is an adeno-associated virus serotype 9 (AAV9) gene therapy. AAV9 is selected for CNS applications because it can cross the blood-brain barrier and transduce neurons efficiently after intravenous administration, which is the critical property that makes it suitable for addressing the neurological pathology in MPS IIIA.
The therapy delivers a functional copy of the SGSH gene under the control of a promoter designed to drive expression in cells throughout the body, including the central nervous system. Once transduced, cells begin producing functional sulfamidase enzyme, which can then begin breaking down the accumulated heparan sulfate substrate. The enzyme produced in transduced cells can also be taken up by neighboring, non-transduced cells through a process called cross-correction, extending the therapy’s reach beyond the cells directly infected by the viral vector.
UX111 is administered as a single intravenous infusion. It is not a continuous therapy requiring repeated dosing. The one-time administration is designed to provide durable gene expression over years, which is both the key clinical advantage and one of the central questions the FDA’s review will focus on: how durable is the effect, and for how long?
The therapy was originally developed by Abeona Therapeutics before being transferred to Ultragenyx, which completed the clinical development program and built out manufacturing capacity. If approved, UX111 will be manufactured entirely within the United States at Andelyn Biosciences in Columbus, Ohio, and at Ultragenyx’s gene therapy manufacturing facility in Bedford, Massachusetts.
The Clinical Evidence: Eight Years of Follow-Up Data
The BLA accepted by the FDA on April 2, 2026 is built on a clinical program that has been running since 2015. The primary study is NCT02716246, a Phase 1/2/3 gene transfer clinical trial conducted across multiple sites.
The data package includes two categories of evidence that together form the basis for the accelerated approval application: biomarker data (cerebrospinal fluid heparan sulfate levels) and functional clinical data across multiple developmental domains.
Biomarker evidence: CSF heparan sulfate reduction
Cerebrospinal fluid heparan sulfate (CSF-HS) is the primary biomarker for MPS IIIA disease activity. Elevated CSF-HS directly reflects the accumulation of toxic substrate in the CNS. Sustained reduction of CSF-HS is the proposed intermediate clinical endpoint for the accelerated approval, as agreed with the FDA during the prior clinical review.
Across the trial cohort, UX111 produced a median reduction of approximately 63.98% in CSF-HS levels (p less than 0.001) over a median follow-up of approximately 4.8 years. An earlier data analysis using time-normalized area under the curve (AUC) methodology to capture cumulative substrate reduction across the full follow-up period found a mean reduction of 63% (p less than 0.0001). The reductions were sustained and not limited to early post-treatment timepoints, supporting the durability of the gene expression.
Functional clinical data: separation from natural history
Because MPS IIIA is a progressive disease with a well-characterized natural history trajectory, treated patients can be compared to what the expected course of the disease would be without intervention. This natural history comparison is the primary method for evaluating functional benefit in the absence of a randomized placebo-controlled trial, which is not ethically feasible in a fatal pediatric disease.
| Outcome measure | Finding | Statistical significance |
|---|---|---|
| Bayley-III cognitive composite (early-stage patients) | +23.2-point gain versus natural history | p less than 0.0001 |
| Communication skills retention | Maintained beyond ages when untreated peers typically lose language | Significant separation from natural history |
| Ambulation | Continued walking beyond expected loss age in many treated patients | Significant separation from natural history |
| Self-feeding | Retained in treated patients beyond typical loss age in untreated peers | Significant separation from natural history |
| CSF heparan sulfate reduction | Median 63.98% reduction | p less than 0.001 |
| Follow-up duration | Up to 8 years; median approximately 4.8 years | Longest follow-up in any MPS IIIA therapeutic program |
Source: Ultragenyx press release February 3, 2026. WORLDSymposium 2026 presentation. NCT02716246.
The 23.2-point Bayley-III cognitive gain in early-stage patients is the most clinically striking number in the dataset. The Bayley Scales of Infant and Toddler Development (Bayley-III) is a standardized developmental assessment. A 23-point gain against a natural history trajectory that is declining represents the children treated with UX111 not just slowing their decline but functioning meaningfully better than where their disease would have taken them without treatment.
The consistency of the results across age groups and disease severity levels at enrollment is also significant. Children who were treated at earlier stages of disease showed the largest functional gains, which is consistent with the biology: gene therapy that reduces substrate accumulation is more effective when there is less existing neuronal damage to overcome. But even children treated at more advanced disease stages showed meaningful separation from natural history in terms of skill retention.
Ultragenyx’s Chief Scientific Officer characterized the data at the time of the BLA resubmission as demonstrating “a remarkable and unprecedented separation from the natural history of Sanfilippo syndrome through more than eight years of follow-up, with children in their teens retaining skills at an age when many of their untreated peers have sadly lost them.”
The Regulatory History: Why This Is a Resubmission
Understanding why this is a resubmitted BLA rather than an initial submission requires knowing what happened the first time.
Ultragenyx originally submitted the UX111 BLA to the FDA and received a Complete Response Letter, meaning the FDA determined the application was not approvable as submitted and identified deficiencies that needed to be addressed before approval could be considered.
The specific deficiencies cited in the CRL centered on the evidentiary standard for the intermediate clinical endpoint supporting accelerated approval. The FDA’s position was that additional long-term clinical data on neurological function would be needed to support the proposed surrogate endpoint of CSF-HS reduction as reasonably likely to predict clinical benefit. Ultragenyx and the FDA agreed during subsequent discussions on what additional data would be required, and the company continued following patients and collecting data.
The resubmission in January 2026, accepted on April 2, 2026, includes those agreed-upon longer-term data. The FDA’s acceptance with a PDUFA date confirms that the agency considers the resubmission complete and the identified deficiencies addressed. It does not guarantee approval but indicates that the evidentiary package meets the threshold for full review.
The FDA granted the UX111 BLA Priority Review in February 2025, which compresses the review timeline from the standard 12 months to 6 months. The September 19, 2026 PDUFA date reflects Priority Review timing from the January 2026 resubmission.
| What accelerated approval means for UX111 Accelerated approval is an FDA pathway that allows approval of drugs for serious conditions based on a surrogate or intermediate clinical endpoint that is reasonably likely to predict clinical benefit, rather than requiring demonstration of direct clinical benefit in pivotal trials. For UX111, the proposed surrogate endpoint is CSF heparan sulfate reduction, which is biologically linked to the neurological pathology: less HS accumulation in the CNS should translate to less neuronal damage and better preservation of function. The additional clinical data in the resubmission, showing functional gains on Bayley-III and other measures alongside the CSF-HS reductions, provides supporting evidence that the surrogate is tracking real neurological benefit. If UX111 receives accelerated approval, continued approval would be contingent on verification of clinical benefit in a confirmatory trial. This is the standard condition of accelerated approval across all indications. For a disease as rare as MPS IIIA, designing and executing a confirmatory trial after approval raises its own logistical questions that the field will need to navigate. |
|---|
Regulatory Designations and Their Significance
UX111 holds multiple regulatory designations in the United States and Europe, each reflecting a different aspect of its development program:
| Designation | Grantor | What it means |
|---|---|---|
| Priority Review | FDA (February 2025) | Compresses review timeline to 6 months from standard 12 |
| Regenerative Medicine Advanced Therapy (RMAT) | FDA | Intensive FDA guidance and interaction; eligibility for accelerated approval, priority review, rolling review |
| Fast Track | FDA | More frequent FDA meetings; rolling review eligibility |
| Rare Pediatric Disease | FDA | Eligible for priority review voucher upon approval |
| Orphan Drug | FDA | 7 years market exclusivity; tax credits for clinical development |
| PRIME designation | EMA | Enhanced early dialogue and guidance for promising medicines |
| Orphan Medicinal Product | EMA | European market exclusivity for 10 years |
The Rare Pediatric Disease designation is worth specific attention. If UX111 is approved under this designation, Ultragenyx would receive a Priority Review Voucher (PRV) that can be used by the company or sold to another pharmaceutical company to accelerate a different drug’s FDA review. These vouchers have sold for hundreds of millions of dollars and represent a significant financial incentive structure that Congress created specifically to encourage development of therapies for rare pediatric diseases.
Safety: What the Clinical Program Shows
Across the clinical trials with follow-up of up to 8 years, UX111 has maintained what Ultragenyx describes as an acceptable and favorable safety profile. No unexpected or serious safety signals have been identified in the long-term follow-up data.
The general safety considerations for AAV9 gene therapy apply to UX111:
Immune responses: AAV capsid can trigger immune responses. Patients with pre-existing immunity to AAV9 (neutralizing antibodies) are typically screened and may be ineligible for treatment. The immune response to the viral vector is a key safety monitoring point in the weeks immediately following infusion.
Liver enzyme elevations: Transient elevations in liver enzymes are a known effect of AAV gene therapies, reflecting immune-mediated responses to transduced hepatocytes. Corticosteroid prophylaxis is used to manage these responses and has been incorporated into the treatment protocol.
Long-term gene expression: While durable expression is the goal, the long-term behavior of AAV9 in pediatric patients who are still growing and developing is an area of ongoing monitoring. The 8-year follow-up data is reassuring on this point but continued surveillance is appropriate.
Genotoxicity: Insertional mutagenesis from AAV vectors is considered low-risk compared to integrating viral vectors, but it is not zero, and long-term registry follow-up is standard practice for gene therapy recipients.
The full prescribing information, when and if it is issued, will contain the complete safety profile from the clinical program.
What This Means for Families Affected by MPS IIIA
If your child has been diagnosed with Sanfilippo syndrome Type A, or you are supporting a family navigating this diagnosis, here is what the September 19, 2026 PDUFA date means and does not mean:
BLA acceptance is not approval. The FDA has accepted the application for review and set a decision target date. The agency will conduct its own independent analysis of all submitted data. The outcome could be approval, a request for additional information, or another Complete Response Letter.
The PDUFA date is a target, not a guarantee. Decisions can come on or before the PDUFA date. The FDA could also extend the review if it identifies issues requiring additional analysis.
Earlier treatment appears to produce better outcomes. The clinical data consistently shows that children treated at earlier disease stages had larger functional gains. If UX111 is approved, treatment timing relative to disease stage will likely be a central clinical consideration.
No treatment is currently approved. While the BLA is under review, MPS IIIA remains without any disease-modifying approved therapy. Families should continue working with metabolic disease specialists at centers with lysosomal storage disorder expertise.
Clinical trial participation remains available. NCT02716246 continues to follow existing participants. Families interested in clinical trial options can search ClinicalTrials.gov for currently enrolling studies.
The most current patient-facing resources are maintained by the National MPS Society, which provides disease information, family support, and physician referral guidance. The NORD rare disease database also maintains a current overview of MPS IIIA. The NIH Genetic and Rare Diseases Information Center provides clinical and research information including ongoing trial listings.
For context on how the FDA has approached other gene therapy approvals for rare pediatric diseases, including the recent approval of the first gene therapy for genetic deafness, see our post on Otarmeni and what the first gene therapy approval under the CNPV program means for the field.
Sources
FDA BLA acceptance press release: Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA). GlobeNewswire. April 2, 2026.
BLA resubmission press release: Ultragenyx Resubmits Biologics License Application for UX111. Ultragenyx IR. January 30, 2026.
Long-term clinical data press release: Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS. GlobeNewswire. February 3, 2026.
CSF-HS correlation data: Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid. Ultragenyx IR.
Clinical trial registration: NCT02716246. Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.HsGSH for MPS IIIA. ClinicalTrials.gov.
MPS IIIA disease overview: Mucopolysaccharidosis Type IIIA. StatPearls. NCBI.
Heparan sulfate and MPS IIIA biology: Heparan Sulfate Proteoglycans in Neurodegeneration. PMC5026768.
NIH GARD MPS IIIA: Mucopolysaccharidosis type IIIA. rarediseases.info.nih.gov.
Accelerated approval pathway: Accelerated Approval. FDA.gov.
RMAT designation: Regenerative Medicine Advanced Therapy Designation. FDA.gov.
Rare Pediatric Disease PRV: Rare Pediatric Disease Priority Review Voucher Program. FDA.gov.
Bayley-III assessment: Bayley Scales of Infant and Toddler Development. PMC6052512.
ERT limitations in MPS: Enzyme Replacement Therapy for Lysosomal Storage Disorders. PMC5814258.
Patient resources: National MPS Society | NORD: MPS III | NIH GARD | ClinicalTrials.gov: MPS IIIA
| Disclaimer: Health Evidence Digest provides general information about FDA regulatory actions and health research for educational purposes. This content is not a substitute for professional medical advice. UX111 (rebisufligene etisparvovec) is not yet FDA-approved. Families navigating a Sanfilippo syndrome Type A diagnosis should work with a metabolic disease specialist at a center with lysosomal storage disorder expertise. |
|---|
